Marc Casper has been appointed to the newly created position of chief operating officer at Thermo Fisher Scientific, the company said last week. Casper had been president of Thermo Fisher’s Analytical Technologies business since the merger of Thermo Electron and Fisher Scientific in late 2006.
Casper joined the company in 2001 as president of its Life and Laboratory Sciences unit. He previously was president, CEO and director of Kendro Laboratory Products and prior to that was president-Americas for Dade Behring.
PerkinElmer said this week that Jeff Capello has resigned as the company’s CFO effective June 6, to pursue other interests. Michael Battles will replace Capello on an interim basis. Capello is currently the company’s vice president and controller.
Capello joined PerkinElmer in 2001 as controller for the analytical Instruments business. Prior to that, he held several positions at Deloitte & Touche.
NextGen last week announced the appointments of Ruth VanBogelen as director of biomarkers and proteomics, and Walid Qorenfleh as vice president of business development.
VanBogelen comes from Pfizer where she was director of proteomics for research and development. Prior to Pfizer, she was at the University of Michigan Medical Center where she led research into microbial proteomics. She currently is on the editorial boards of the journals Proteomics, Proteomics Clinical Applications, and the Journal of Proteomics and Bioinformatics.
Qoronfleh comes from the Q3 Consulting Group, which he founded and where he was managing director. He also has held various senior management and executive positions at AntexPharma, Pierce Biotechnology, now part of Thermo Fisher Scientific, and CTA Corp/University of Michigan.